Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squ...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-10, Vol.125 (9), p.1210-1216
Main Authors: Lindsay, Colin R., Shaw, Emily C., Moore, David A., Rassl, Doris, Jamal-Hanjani, Mariam, Steele, Nicola, Naheed, Salma, Dick, Craig, Taylor, Fiona, Adderley, Helen, Black, Fiona, Summers, Yvonne, Evans, Matt, Rice, Alexandra, Fabre, Aurelie, Wallace, William A., Nicholson, Siobhan, Haragan, Alex, Taniere, Phillipe, Nicholson, Andrew G., Laing, Gavin, Cave, Judith, Forster, Martin D., Blackhall, Fiona, Gosney, John, Popat, Sanjay, Kerr, Keith M.
Format: Article
Language:English
Subjects:
631/67/1612/1350
692/4028/67/1612
692/4028/67/1612/1350
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Large Cell - metabolism
Carcinoma, Large Cell - pathology
Carcinoma, Large Cell - therapy
Carcinoma, Neuroendocrine - metabolism
Carcinoma, Neuroendocrine - pathology
Carcinoma, Neuroendocrine - therapy
Clinical Trials as Topic
Consensus
Consensus Statement
Drug Resistance
Epidemiology
Humans
Immunotherapy
Lung cancer
Lung carcinoma
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Molecular Medicine
Neuroendocrine tumors
Non-small cell lung carcinoma
Oncology
Precision Medicine
Small cell lung carcinoma
Thorax
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-021-01407-9